Results 241 to 250 of about 85,510 (321)

Pathways to Progressive Disability in Multiple Sclerosis: The Role of Glial Cells in Chronic CNS Inflammation

Glia, EarlyView.
ABSTRACT Multiple sclerosis (MS) is the most common non‐infectious inflammatory CNS disease, characterized by progressive neurodegeneration and focal demyelinated lesions. Traditionally considered an autoimmune disease, MS is driven by the immune system's attack on CNS myelin, resulting in cumulative disability.
Volker Siffrin
wiley   +1 more source

P3‐251: Binding of a beta‐amyloid 1‐42 peptide to human albumin grifols^® [PDF]

, 2009
Montserrat Costa, Anna Ma Ortiz, Juan I. Jorquera   +2 more
openalex   +1 more source

Cordycepin mediates neuroprotection against apoptosis via ERK/CREB signaling activation in Aβ1–42‐induced neuronal cell models

Ibrain, Volume 11, Issue 1, Page 84-97, Spring 2025.
This study demonstrates cordycepin's neuroprotective effects against Aβ1–42‐induced apoptosis in neuronal cells, mediated through the activation of the extracellular signal‐regulated kinase/cyclic AMP‐responsive element‐binding protein (ERK/CREB) signaling pathway.
Wenshu Zhou, Cheng Wang, Yige Tan, Philip Lazarovici, Xiaoyan Wen, Shaoping Li, Wenhua Zheng   +6 more
wiley   +1 more source

Amyloid beta peptides, locus coeruleus-norepinephrine system and dense core vesicles. [PDF]

Brain Res, 2019
Ross JA, Reyes BAS, Van Bockstaele EJ.
europepmc   +1 more source

Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals.

, 1997
Qing Guo, Bryce L. Sopher, Katsutoshi Furukawa, Dao G. Pham, Nic Robinson, George M. Martin, Mark P. Mattson   +6 more
openalex  

Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions

Ibrain, EarlyView.
Alzheimer's disease treatment is evolving rapidly, with emerging strategies targeting multiple disease pathways. This graphical abstract highlights the shift from traditional therapies to innovative approaches that hold promise for improving outcomes.
Tapas Kumar Mohapatra, Reena Rani Nayak, Ankit Ganeshpurkar, Prashant Tiwari, Dileep Kumar   +4 more
wiley   +1 more source

Localization of amyloid beta peptides to locus coeruleus and medial prefrontal cortex in corticotropin releasing factor overexpressing male and female mice. [PDF]

Brain Struct Funct, 2019
Ross JA, Alexis R, Reyes BAS, Risbrough V, Van Bockstaele EJ.   +4 more
europepmc   +1 more source

The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey [PDF]

, 2017
Bateman, Randy J, et al,
core   +2 more sources

Immunomodulatory natural polysaccharide‐based nanoparticles for the treatment of neurodegenerative diseases

Ibrain, EarlyView.
Polysaccharide‐based nanoparticles offer versatile platforms for drug delivery and immune modulation in neurodegenerative diseases. This review highlights their potential in treating Alzheimer's, Parkinson's, and multiple sclerosis, focusing on targeted delivery and neuroinflammation.
Leto‐Aikaterini Tziveleka, Mariafrancesca Cascione, Paolo Pellegrino, Annalisa Bianco, Stefano Leporatti, Valeria De Matteis   +5 more
wiley   +1 more source

Aggregation States of Aβ_1-40, Aβ_1-42 and Aβp_3-42 Amyloid Beta Peptides: A SANS Study. [PDF]

Int J Mol Sci, 2019
Festa G, Mallamace F, Sancesario GM, Corsaro C, Mallamace D, Fazio E, Arcidiacono L, Garcia Sakai V, Senesi R, Preziosi E, Sancesario G, Andreani C.   +11 more
europepmc   +1 more source